BGB-16673 (BGB-16673, BTK-IN-29) is an orally active, selectively chimeric degradation activator compound (CDAC), targeting BTK (IC50=0.69 nM). BGB-16673 ligates BTK to E3 ubiquitin ligase, causing BTK to undergo polyubiquitination, which is then recognized and degraded by the proteasome, thereby exerting efficient BTK degradation activity. BGB-16673 can be used in the research of B-cell malignancies such as chronic lymphocytic leukemia, small lymphocytic lymphoma, and mantle cell lymphoma[1][2][3].
Molecular Weight:
851.01
Purity:
97.79
CAS Number:
[2736508-60-2]
Formula:
C47H54N12O4
Target:
Btk,PROTACs
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
